Effects of intravenous and intraduodenal fat on jejunal motility and on plasma cholecystokinin in man
- PMID: 3359909
- DOI: 10.1007/BF01798357
Effects of intravenous and intraduodenal fat on jejunal motility and on plasma cholecystokinin in man
Abstract
The effects of intravenous and intraduodenal fat on jejunal motility were studied in nine normal volunteers. Using a nitrogen hydraulic infusion system, recording was performed continuously during 4 hr of fasting and 5 hr of 100 ml/hr infusion of fat (Intralipid 10%) given either intraduodenally (group ID) or intravenously (group IV) and 9 hr after the end of fat administration successively. The two experiments were performed at seven-day intervals in random order. In six of the nine subjects, a third experiment, in which 20 g of cholestyramine was given by mouth during intraduodenal fat infusion (group ID + C), was carried out. Venous blood samples were drawn for measurement of serum triglyceride levels and radioimmunoassay of plasma cholecystokinin. Intraduodenal fat, alone or plus cholestyramine, induced a significant reduction in incidence of phase III of the migrating motor complex. Intravenous fat reduced the incidence of phase III. However, this reduction was significant only during the last 3 hr of fat infusion, corresponding to the highest serum triglyceride concentration. In the three groups, fat infusion induced a significant increase in duration of phase II, leading to a postprandial-like pattern. Plasma cholecystokinin increased significantly in the three groups during fat administration, with a significant positive correlation between serum triglyceride concentration and plasma cholecystokinin in the group IV. The data suggest that, in addition to its known inhibitory effects on activity fronts when acting luminally, fat given intravenously may inhibit phase III activity. The effects in both instances may be mediated in part by cholecystokinin.
Similar articles
-
Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide.Gut. 1994 Apr;35(4):501-5. doi: 10.1136/gut.35.4.501. Gut. 1994. PMID: 8174988 Free PMC article. Clinical Trial.
-
Effect of intravenous fat on cholecystokinin secretion and gallbladder motility in man.JPEN J Parenter Enteral Nutr. 1992 Jan-Feb;16(1):16-9. doi: 10.1177/014860719201600116. JPEN J Parenter Enteral Nutr. 1992. PMID: 1738213
-
Intraduodenal conjugated bile salts exert negative feedback control on gall bladder emptying in the fasting state without affecting cholecystokinin release or antroduodenal motility.Gut. 2002 May;50(5):669-74. doi: 10.1136/gut.50.5.669. Gut. 2002. PMID: 11950814 Free PMC article.
-
Effect of intravenous lipid on gastric acid secretion stimulated by intravenous amino acids.Gastroenterology. 1980 Nov;79(5 Pt 1):873-6. Gastroenterology. 1980. PMID: 7419011 Clinical Trial.
-
Acute intraduodenal bile salt depletion leads to strong gallbladder contraction, altered antroduodenal motility and high plasma motilin levels in humans.Neurogastroenterol Motil. 2000 Oct;12(5):421-30. doi: 10.1046/j.1365-2982.2000.00217.x. Neurogastroenterol Motil. 2000. PMID: 11012942
Cited by
-
Effects of amoxicillin-clavulanate combination on the motility of the small intestine in human beings.Antimicrob Agents Chemother. 1991 Jun;35(6):1085-8. doi: 10.1128/AAC.35.6.1085. Antimicrob Agents Chemother. 1991. PMID: 1929247 Free PMC article. Clinical Trial.
-
Jejunal motility during cyclic total parenteral nutrition in patients with Crohn's disease.Gut. 1989 Jun;30(6):815-9. doi: 10.1136/gut.30.6.815. Gut. 1989. PMID: 2502485 Free PMC article.
-
Fat preload delays gastric emptying: reversal by cisapride.Br J Clin Pharmacol. 1990 Dec;30(6):839-45. doi: 10.1111/j.1365-2125.1990.tb05449.x. Br J Clin Pharmacol. 1990. PMID: 2288830 Free PMC article. Clinical Trial.
-
Intestinal manometry: who needs it?Gastroenterol Hepatol Bed Bench. 2015 Fall;8(4):246-52. Gastroenterol Hepatol Bed Bench. 2015. PMID: 26468344 Free PMC article. Review.
-
Slow gastric emptying induced by high fat content of meal accelerated by cisapride administered rectally.Dig Dis Sci. 1991 Sep;36(9):1259-65. doi: 10.1007/BF01307519. Dig Dis Sci. 1991. PMID: 1893810 Clinical Trial.